Johnson & Johnson (JNJ)

Johnson & Johnson’s adjusted EPS topped expectations while revenue came in line in the second fiscal quarter of 2026, reported July 15, 2026. Revenue rose 6.6% to about $25.3 billion (up from about $23.7 billion a year ago), with results spanning its Innovative Medicine and MedTech franchises, and adjusted EPS of $2.90 topped the $2.84 estimate (+2.1%) while revenue of $25.310 billion was in line with the $25.062 billion estimate (+0.99%). On profitability, gross margin was about 73% and operating margin was near 28%, with operating income around $7.2 billion on gross profit of roughly $18.5 billion. Net income was roughly $5.5 billion, down 0.1% from about $5.5 billion a year ago, while adjusted EPS was up 4.7% from $2.77. The company generated about $4.7 billion of operating cash flow, repurchased roughly $221 million of stock, and paid about $3.2 billion in dividends during the quarter. For the next period, consensus calls for EPS of $2.95 on revenue of $25.318 billion.